Bartlett, Cynthia Huang
Pfizer (United States)
3 papers on CoChatORCID 0000-0003-2003-2213
Most cited papers
- Verified
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
Cristofanilli, M., Turner, N. C., Bondarenko, I., Ro, J., Im, S.-A., Masuda, N., Colleoni, M., DeMichele, A., Loi, S., Verma, S., et al. (2016) · The Lancet Oncology
Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies
Cited by 1,827
- Verified
Plasma ESR1 Mutations and the Treatment of Estrogen Receptor–Positive Advanced Breast Cancer
Fribbens, C., O’Leary, B., Kilburn, L., Hrebien, S., Garcia-Murillas, I., Beaney, M., Cristofanilli, M., Andre, F., Loi, S., Loibl, S., et al. (2016) · Journal of Clinical Oncology
Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies
Cited by 722
- Verified
Palbociclib plus letrozole as first-line therapy in estrogen receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer with extended follow-up
Rugo, H. S., Finn, R. S., Diéras, V., Ettl, J., Lipatov, O., Joy, A. A., Harbeck, N., Castrellon, A., Iyer, S., Lu, D. R., et al. (2019) · Breast Cancer Research and Treatment
Advanced Breast Cancer TherapiesBreast Cancer Treatment Studies
Cited by 443
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free